Crossmark

Response to “Comment on: Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety”

Crossref DOI link: https://doi.org/10.1007/s40261-021-01050-5

Published Online: 2021-06-10

Published Print: 2021-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Young R. https://orcid.org/0000-0002-7677-2125
License Information

Text and Data Mining valid from 2021-06-10

Version of Record valid from 2021-06-10
More Information

Article History

Accepted: 28 May 2021

First Online: 10 June 2021

Declarations

:

: No sources of funding were obtained for this response to comment.

: Young R. Lee declares there are no conflicts of interest to disclose.

Document is current

Any future updates will be listed below